A combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia and its application

Through the combination of PPAR agonists and Bcl-2 inhibitors, PPARα is activated, and the proliferation and clonal formation of AML cells are inhibited, which solves the problem of poor drug resistance and single-drug therapy in the treatment of acute myeloid leukemia, which significantly improves the The apoptosis and inhibition of AML cells provide new therapeutic strategies.

CN114949230BActive Publication Date: 2024-12-06SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210664602.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-06-13
Publication Date
2024-12-06
Estimated Expiration
2042-06-13

AI Technical Summary

Technical Problem

The treatment plans for acute myeloid leukemia in the prior art have drug resistance problems, single drug therapy is poor, and there is a lack of effective drug combination strategies. New treatment plans need to be developed to extend patient survival time and improve cure rates.

Method used

Using a combination of PPAR agonist and Bcl-2 inhibitor, the PI3K/AKT and Raf/MEK/ERK pathways are activated, and the proliferation and clonal formation of AML cells are inhibited, thereby inducing cell apoptosis, thereby inhibiting the development of AML. .

Benefits of technology

It significantly improves the sensitivity of AML cells to drugs, enhances the inhibitory effect of apoptosis and clonal formation of AML cells, provides an effective drug combination strategy, extends the apoptosis time of AML cells and inhibits the disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114949230B_ABST
    Figure CN114949230B_ABST
Patent Text Reader

Abstract

The present invention relates to a combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia and its application, wherein the combined pharmaceutical composition comprises a PPAR agonist and a Bcl-2 inhibitor. The present invention has found that a PPAR agonist combined with a Bcl-2 inhibitor has a more significant effect of inhibiting AML cell proliferation, inducing AML cell apoptosis, and inhibiting AML cell clone formation ability than a single PPAR agonist or a Bcl-2 inhibitor. The present invention provides an effective drug combination strategy for the treatment of acute myeloid leukemia, which is of great significance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, relates to a new method for preventing or treating acute myeloid leukemia, and relates to a combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia and its application. Background Art

[0002] Acute myeloid leukemia (AML) is a highly heterogeneous blood malignancy characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow and blood and interference with the growth of normal blood cells. Although the current first-line treatment regimen of cytarabine combined with anthracycline chemotherapy can relieve most patients, most AML patients will relapse, and the current treatment situation is not optimistic. The main reason for chemotherapy failure is that AML patients develop resistance to chemotherapy. Therefore, there is an urgent need to find new AML treatment options to prolong the survival time of patients and improve the cure rate of patients.

[0003] Bcl-2 inhibitors can specifically target Bcl-2 and inhibit its anti-apoptotic function, thereby mediating the apoptosis of tumor cells and exercising tumor cell killing function. Existing research results show that overexpression of anti-apoptotic Bcl-2 family proteins is closely related to AML chemotherapy resistance and poor prognosis. Therefore, by targeting and inhibiting anti-apoptotic Bcl-2 family proteins, lowering the threshold of apoptosis has become a potential solution for the treatment of AML. ABT-199 (Venetoclax) is the world's first small molecule inhibitor targeting protein-protein interaction (PPI). It is a highly effective, selective and orally active small molecule Bcl-2 inhibitor that can bind to the hydrophobic groove of Bcl-2 and destroy the interaction between Bcl-2 molecules and pro-apoptotic proteins (such as Bax). ABT-199 was approved by the FDA in 2016 for the treatment of hematological tumors such as chronic lymphocytic leukemia, but its monotherapy results are poor and it is easy to develop drug resistance. Therefore, a reasonable combination approach may be needed to improve the efficacy of ABT-199 in AML.

[0004] CN109641002A discloses a combination of a telomerase inhibitor and a Bcl-2 inhibitor for treating blood cancers, including AML. The telomerase inhibitor is imetelstat or imetelstat sodium, and the Bcl-2 inhibitor is ABT-199. Studies have shown that the synergistic effect of the telomerase inhibitor and the Bcl-2 inhibitor is used to induce a higher level of apoptosis in AML cells than any drug alone.

[0005] However, there are relatively few effective drug combination strategies disclosed in the prior art for treating acute myeloid leukemia, and it is very meaningful to develop more new strategies for treating acute myeloid leukemia. Summary of the invention

[0006] In view of the deficiencies of the prior art, the purpose of the present invention is to provide a new method for preventing or treating acute myeloid leukemia, and to provide a combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia and its application.

[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0008] In a first aspect, the present invention provides a combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia, wherein the combined pharmaceutical composition comprises a PPAR agonist and a Bcl-2 inhibitor.

[0009] The combined pharmaceutical composition involved in the present invention creatively combines PPAR agonists and Bcl-2 inhibitors as a drug for preventing or treating acute myeloid leukemia, wherein the PPAR agonist can not only bind to PPARα and activate PPARα, but also inhibit the PI3K expression level of AML cell lines at the molecular level, and in combination with Bcl-2 inhibitors downregulate the PI3K / AKT pathway and the Raf / MEK / ERK pathway, and can inhibit the proliferation of AML cell lines, induce their apoptosis level, and inhibit the cloning ability of AML cell lines at the cellular level, and finally inhibit the occurrence and development of AML. The present invention has found that the combination of PPAR agonists and Bcl-2 inhibitors has a more significant effect of inhibiting AML cell proliferation, inducing AML cell apoptosis, and inhibiting AML cell cloning ability than a single PPAR agonist or Bcl-2 inhibitor. The present invention provides an effective drug combination strategy for the treatment of acute myeloid leukemia, which is of great significance.

[0010] Preferably, the PPAR agonist includes: Chiglitazar, Fenofibrate, Gemfibrozil, Fenofibric acid, Flufenamic acid, Ibuprofen, Bezafibrate, Indomethacin, Rosiglitazone, Ciprofibrate, Valproicacid, Dexibuprofen, Amiodarone, Prasterone, alpha-Linolenic acid, PPM-204, Clinofibrate, Myrrh, Palmitic Acid, Fenoprofen, Lauric Acid, Stearic Acid. acid), Clofibrate, Doconexent, Oleic Acid, Troglitazone, Omega-3 fatty acids, Icosapent, Myristic acid, Arachidonic Acid, Isoflavone, Aleglitazar, Reglitazar, Elafibranor, Muraglitazar, Ertiprotafib, Phthalic Acid, Ragaglitazar, Tesaglitazar, GW-590735, Leukotriene B4, Caprylic Acid acid), GW501516 (Cardarine), resveratrol (Resveratrol), N, N-bis (3- (D-gluconamido) propyl) deoxycholamide (N, N-Bis (3- (D-gluconamido) propyl) deoxycholamide) or any one or a combination of at least two of the above compounds in a pharmaceutically acceptable salt, isomer, solvate, metabolite.

[0011] Preferably, the PPAR agonist is cigligliptin or any one of its pharmaceutically acceptable salts, isomers, solvates, metabolites, or a combination of at least two thereof.

[0012] Preferably, the pharmaceutically acceptable salt includes any one of an alkali metal salt, an alkaline earth metal salt, an ammonium salt or a quaternary ammonium salt, preferably an alkali metal salt, and more preferably a sodium salt or a potassium salt.

[0013] Preferably, the PPAR agonist is sitagliptin sodium, sitagliptin potassium or the levorotatory isomer thereof.

[0014] Preferably, the Bcl-2 inhibitor includes any one of ABT-199 (Venetoclax), ABT-737 or ABT-263 (Navitoclax) or a combination of at least two thereof.

[0015] The present invention has demonstrated in AML cell lines that the combination of PPAR agonist Siglitazar (Chiglitazar) and Bcl-2 inhibitor ABT-199 (Venetoclax) can inhibit the proliferation of AML cells and induce apoptosis, and can also inhibit the cloning ability of AML cell lines. In terms of mechanism, Siglitazar can bind to PPARα and activate the protein expression of PPARα in AML cells. PPARα interacts with the PI3K promoter to inhibit the expression level of this gene, thereby downregulating AKT on the one hand, and inducing apoptosis of AML cells in combination with the Bcl-2 inhibitor ABT-199; on the other hand, it inhibits the proliferation of AML cells by downregulating the Raf / MEK / ERK pathway, and ultimately inhibits the occurrence and development of AML. The schematic diagram of its mechanism of action for inhibiting the occurrence and development of AML is shown below. Figure 1 shown.

[0016] Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

[0017] Preferably, the combination pharmaceutical composition of the present invention can be administered alone or in combination with excipients to make an appropriate dosage form for administration. The pharmaceutically acceptable excipients include any one or a combination of at least two of carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers.

[0018] The combination of at least two agents, for example, a combination of a diluent and an excipient, a combination of an emulsifier and a solubilizer, a combination of a filler, an adhesive and a wetting agent, etc., any other combination can be selected and will not be described in detail here.

[0019] Preferably, the combination pharmaceutical composition is a single compound preparation or a combination of two separate preparations.

[0020] Preferably, the combined pharmaceutical composition is a combination of two separate preparations, and the two separate preparations are administered simultaneously or sequentially.

[0021] The combination pharmaceutical composition may be in the form of a single compound preparation or a combination of two separate preparations; when it is a combination of two separate preparations, the administration method may be simultaneous administration, cross administration or sequential administration.

[0022] Preferably, the preparation is any pharmaceutically acceptable dosage form, such as tablets, powders, suspensions, granules, capsules, solutions, enemas, emulsions, etc.

[0023] In a second aspect, the present invention provides a use of the combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect in the preparation of a drug for preventing, alleviating or treating acute myeloid leukemia.

[0024] In a third aspect, the present invention provides a use of the combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect in the preparation of an acute myeloid leukemia cell proliferation inhibitor.

[0025] In a fourth aspect, the present invention provides a use of the combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect in the preparation of an acute myeloid leukemia cell proliferation inhibitor for non-diagnostic and / or therapeutic purposes.

[0026] According to the research results of the present invention, the combined pharmaceutical composition has a significant effect of inhibiting the proliferation of acute myeloid leukemia cells. Therefore, the results indicate that the combined pharmaceutical composition can be used as an acute myeloid leukemia cell proliferation inhibitor for non-diagnostic and / or therapeutic purposes, and can be used in the field of scientific research, such as studying more acute myeloid leukemia cell growth and metabolic mechanisms or behaviors, screening drugs for treating acute myeloid leukemia, etc.

[0027] In a fifth aspect, the present invention provides a use of the combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect in the preparation of an apoptosis promoter for acute myeloid leukemia cells.

[0028] In a sixth aspect, the present invention provides a use of the combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect in the preparation of an apoptosis promoter for acute myeloid leukemia cells for non-diagnostic and / or therapeutic purposes.

[0029] According to the research results of the present invention, the combined pharmaceutical composition has a significant effect of inducing apoptosis of acute myeloid leukemia cells. Therefore, the results indicate that the combined pharmaceutical composition can be used as an acute myeloid leukemia cell apoptosis promoter for non-diagnostic and / or therapeutic purposes, and can be used in the field of scientific research, such as studying more acute myeloid leukemia cell apoptosis and metabolic mechanisms or behaviors, screening drugs for treating acute myeloid leukemia, etc.

[0030] In a seventh aspect, the present invention provides a use of the combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect in the preparation of an inhibitor of clonal formation of acute myeloid leukemia cells.

[0031] In an eighth aspect, the present invention provides a use of the combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia according to the first aspect in the preparation of a clone formation inhibitor of acute myeloid leukemia cells for non-diagnostic and / or therapeutic purposes.

[0032] According to the research results of the present invention, the combined pharmaceutical composition has the effect of significantly inhibiting the cloning of acute myeloid leukemia cells. Therefore, the results indicate that the combined pharmaceutical composition can be used as a cloning inhibitor of acute myeloid leukemia cells for non-diagnostic and / or therapeutic purposes, and can be used in the field of scientific research, such as studying more acute myeloid leukemia cell clones and metabolic mechanisms or behaviors, screening drugs for treating acute myeloid leukemia, etc.

[0033] In the above application, the acute myeloid leukemia cells include KG-1α cells and / or Kasumi cells.

[0034] Compared with the prior art, the present invention has the following beneficial effects:

[0035] The combined pharmaceutical composition involved in the present invention creatively combines PPAR agonists and Bcl-2 inhibitors as a drug for preventing or treating acute myeloid leukemia, wherein the PPAR agonist can not only bind to PPARα and activate PPARα, but also inhibit the PI3K expression level of AML cell lines at the molecular level, and in combination with Bcl-2 inhibitors downregulate the PI3K / AKT pathway and the Raf / MEK / ERK pathway, and can inhibit the proliferation of AML cell lines, induce their apoptosis level, and inhibit the cloning ability of AML cell lines at the cellular level, and finally inhibit the occurrence and development of AML. The present invention has found that the combination of PPAR agonists and Bcl-2 inhibitors has a more significant effect of inhibiting AML cell proliferation, inducing AML cell apoptosis, and inhibiting AML cell cloning ability than a single PPAR agonist or Bcl-2 inhibitor. The present invention provides an effective drug combination strategy for the treatment of acute myeloid leukemia, which is of great significance. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 Schematic diagram of the mechanism of action of the combined pharmaceutical composition of the present invention in inhibiting the occurrence and development of AML;

[0037] Figure 2A is the result graph of KG1α cell proliferation level in each group;

[0038] Figure 2B is the result graph of the proliferation level of Kasumi cells in each group;

[0039] Figure 3A is a statistical graph of KG1α cell counting results in each group;

[0040] Figure 3B is a statistical graph of the Kasumi cell counting results of each group;

[0041] Figure 4A This is a statistical result of the apoptotic cell ratio after 24 hours of treatment of KG-1α cells with different concentrations of Siglitstat and ABT-199;

[0042] Figure 4B This is a statistical result of the live cell ratio after 24 hours of treating KG-1α cells with different concentrations of Siglitstat and ABT-199;

[0043] Figure 4C This is a statistical graph of the apoptotic cell ratio after 24 hours of treatment of Kasumi cells with different concentrations of Siglitstat and ABT-199;

[0044] Figure 4DThis is a statistical graph of the live cell ratio after 24 hours of treatment of Kasumi cells with different concentrations of Siglitstat and ABT-199;

[0045] Figure 5A This is a diagram showing the results of the identification of cell clone formation ability of KG-1α cells and Kasumi cells after treatment with sitagliptin and ABT-199;

[0046] Figure 5B This is a statistical result diagram of KG-1α cell clone formation;

[0047] Figure 5C This is a statistical result graph of Kasumi cell clone formation;

[0048] Fig. 6A is the Western blot result of protein expression level after treatment with sitagliptin and ABT-199;

[0049] Figure 6B It is a statistical graph of Luc / Rluc results of HEK293T cells co-transfected with pGL3-PI3K, pML-SV40-hRluc and different amounts of pCMV-PPARα;

[0050] Fig. 7A This is a graph showing the Western blot analysis of proliferation-related genes in KG-1α cells and Kasumi cells treated with sitagliptin and ABT-199 for 24 hours;

[0051] Figure 7B This is the Western blot analysis result of apoptosis-related genes in KG-1α cells and Kasumi cells treated with sitagliptin and ABT-199 for 24 hours;

[0052] Fig. 8A This is the appearance of the spleen of each group of mice in the PDX mouse model 14 days after administration;

[0053] Figure 8B This is a statistical chart of spleen weight of mice in each group after 14 days of drug administration in the PDX mouse model;

[0054] Figure 8C This is a statistical result of the ratio of human CD45 positive cells in the leg bone marrow of the PDX mouse model 14 days after administration;

[0055] Fig.8D This is a statistical chart of the survival rate of PDX mouse models 14 days after administration. DETAILED DESCRIPTION

[0056] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only used to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0057] The process, conditions, reagents, experimental methods, etc. for implementing the present invention, except for the contents specifically mentioned below, are all common knowledge and common common sense in the art, and the present invention has no particular restrictions. The experimental methods without specifying specific conditions in the embodiments are usually carried out under conventional conditions or under conditions recommended by the manufacturer.

[0058] Unless otherwise specified, all technical terms and scientific terms used in this specification have the same meaning as those generally understood by those skilled in the art to which the present invention belongs. However, in case of any conflict, the present specification including the definitions shall prevail.

[0059] The drugs ABT-199 (Venetoclax) and Chiglitazar involved in the following examples are both provided by Shenzhen ChipScreen Biopharmaceuticals Co., Ltd.

[0060] AML cell lines (including KG1α and Kasumi) were provided by the Institute of Hematology, Xiamen University School of Medicine.

[0061] Example 1

[0062] Inhibitory effect of combined drug composition on proliferation of AML cell lines

[0063] The operation method is: take the quantity as 1×10 4 AML cell lines in the logarithmic growth phase (including KG1α and Kasumi cell lines) were inoculated in 96-well plates. The control group was treated with DMSO, and the experimental group's sitagliptin sodium concentration gradient was set to 0μM, 0.25μM, 0.5μM, 1μM, 2μM, 4μM, 8μM and 16μM; the ABT-199 concentration gradient was set to 0nM, 2.5nM, 5nM, 10nM, 20nM, 40nM, 80nM and 160nM; after 24h of treatment, the proliferation level of AML cells in different groups was detected by CCK8 kit, and the viable cells were counted by trypan blue staining.

[0064] The results of cell proliferation levels in each group are shown in Figure 2A (KG1α) and Figure 2B (Kasumi)

[0065] The cell counting results of each group are shown in Figure 3A (KG1α) and Figure 3B (Kasumi)

[0066] Combined with the above results, it can be seen that sitagliptin combined with ABT-199 can inhibit the proliferation level of AML cells and show concentration dependence; with the increase of treatment concentration, the inhibition rate gradually increases; compared with the single-drug experimental group, the combination of the two drugs can significantly enhance the sensitivity of KG-1α and Kasumi cells to the drug.

[0067] Example 2

[0068] Apoptosis-inducing effect of combined drug combination on AML cell line

[0069] The operation method is: take the quantity as 1×10 5 AML cell lines in the logarithmic growth phase (including KG1α and Kasumi cell lines) were inoculated in 24-well plates. The control group was treated with DMSO, and the experimental group's sitagliptin sodium concentration gradient was set to 0μM, 0.25μM, 0.5μM, 1μM, 2μM, 4μM, 8μM and 16μM; the ABT-199 concentration gradient was set to 0nM, 2.5nM, 5nM, 10nM, 20nM, 40nM, 80nM and 160nM; after 24h of treatment, the Annexin V / PI kit was used to detect the apoptosis of AML cells in different groups (the specific operation steps were carried out according to the kit instructions).

[0070] Figure 4A and Figure 4B The statistical results of apoptotic cell ratio and live cell ratio after 24 hours of treatment of KG-1α cells with different concentrations of Siglitstat and ABT-199 are shown; Figure 4C and Figure 4D The results of apoptotic cell ratio and live cell ratio were statistically analyzed after 24 hours of treatment of Kasumi cells with different concentrations of sitagliptin and ABT-199.

[0071] From the above results, it can be seen that sitagliptin combined with ABT-199 induces apoptosis of AML cells and increases the apoptosis level of AML cells in a concentration-dependent manner.

[0072] Example 3

[0073] Inhibitory effect of combined drug composition on clone formation of AML cell line

[0074] The operation method is as follows: prepare two low-melting-point agarose solutions of 1.2% and 0.7% respectively with distilled water, and sterilize them by high pressure; mix 1.2% agarose and 2×DMEM culture medium in a ratio of 1:1, and keep the temperature at 40°C; take 3mL of the mixed solution and inject it into a 6cm diameter plate, cool and solidify, and place it in a CO2 incubator as a bottom agar for standby use; mix 0.7% agarose and 2×DMEM culture medium in a ratio of 1:1 in a sterile test tube, add cell suspension (inoculated with 1000 cells) into the tube, mix well, and inject it into the plate with 1.2% agarose as the bottom layer to form a double agar layer;

[0075] The control group was treated with DMSO, the experimental group was treated with sitagliptin sodium at a concentration of 10 μM and ABT-199 at a concentration of 100 nM; after the upper agar solidified, the cells were placed in a 37°C 5% CO2 incubator for 14 days; when the number of cells contained in a single clone was greater than 50, it could be stained with a low concentration of crystal violet solution (0.1%) and the clone formation rate was counted.

[0076] Figure 5A This is the result of identifying the cell clone formation ability of KG-1α cells and Kasumi cells after treatment with sitagliptin and ABT-199; Figure 5B This is a statistical result diagram of KG-1α cell clone formation; Figure 5C This is a statistical graph of Kasumi cell clone formation.

[0077] The results showed that sitagliptin combined with ABT-199 significantly inhibited the clone-forming ability of AML cell lines.

[0078] Example 4

[0079] Effect of Siglitstat on PI3K gene expression in AML cell lines

[0080] The operation method is: take 1×10 6 AML cell lines KG-1α and Kasumi in the logarithmic growth phase were inoculated in 6 cm cell culture dishes respectively; the control group was treated with DMSO, and the experimental group KG1α and Kasumi cells were treated with sitagliptin at a concentration of 10 μM and ABT-199 at a concentration of 50 nM; after 36 h of treatment, the cells were collected by centrifugation at 300 g for 5 min, half of the cells were taken and lysed with 200 μL RIPA lysis buffer on ice for 1 h, the total protein was extracted for Western blot, and the expression levels of PPARα and PI3K related proteins were detected.

[0081] Fig. 6A This is the Western blot result of protein expression level after treatment with sitagliptin and ABT-199. It can be seen from the figure that PPARα expression was significantly upregulated and PI3K expression was significantly downregulated in the sitagliptin monotherapy group and the combination of the two drugs group.

[0082] To investigate whether the transcription factor PPARα regulates PI3K gene expression:

[0083] First, the PI3K promoter sequence was searched using the UCSC database (https: / / genome.ucsc.edu / ) and verified by comparison in NCBI;

[0084] The JASPAR database (https: / / jaspar.genereg.net / ) and the FIMO database (https: / / meme-suite.org / meme / tools / fimo) were used to predict the binding sites of PPARα in the PI3K promoter region.

[0085] The dual luciferase reporter gene system was used to verify that the transcription factor PPARα bound to the PI3K promoter, thereby downregulating the expression level of the gene.

[0086] The promoter fragment of PI3K was cloned into the Luciferase reporter vector (pGL3-basic) to construct the recombinant plasmid pGL3-PI3K promoter;

[0087] PPARα was cloned into pCMV vector to construct the recombinant plasmid pCMV-PPARα;

[0088] When HEK293T cells seeded in 24-well plates grew to a confluency of 70%, 200 ng pGL3-PI3K, 40 ng pML-SV40-hRluc, and pCMV-PPARα (0, 200, 400, 800 ng) were co-transfected using Lipofectamine2000;

[0089] 24-36h after transfection, the culture medium was aspirated, the cells were washed with pre-cooled 1× PBS, 200 μL of Harvest Buffer was added to each well, the cells were placed on ice for 10 min, and the cells were lysed by centrifugation at 10000 rpm for 15 min;

[0090] Take the quantitative supernatant and add an appropriate amount of luciferase substrate. Detect the fluorescence intensity within 30 seconds. The detection value of firefly luciferase / the detection value of Renilla luciferase (Luc / Rluc) is proportional to the intensity of the transcription factor.

[0091] Figure 6BThe Luc / Rluc result statistical chart of HEK293T cells co-transfected with pGL3-PI3K, pML-SV40-hRluc and different amounts of pCMV-PPARα. The results show that the more pCMV-PPARα is transferred, the lower the Luc / Rluc value is, so the transcription factor PPARα can bind to the PI3K promoter and downregulate the expression level of this gene.

[0092] Example 5

[0093] Effect of combined drug combination on PI3K gene expression in AML cell lines

[0094] The operation method is: take 1×10 6 AML cell lines KG-1α and Kasumi in the logarithmic growth phase were inoculated in 6 cm cell culture dishes, respectively; the control group was treated with DMSO, and the experimental group KG1α and Kasumi cells were treated with sitagliptin at a concentration of 10 μM and ABT-199 at a concentration of 50 nM; after 36 h of treatment, the cells were collected by centrifugation at 300 g for 5 min, half of the cells were lysed with 200 μL RIPA lysis buffer on ice for 1 h, and the total protein was extracted for Western blot to detect the expression levels of proteins related to the downstream signaling pathways of PPARα and PI3K.

[0095] Fig. 7A The figure shows the Western blot analysis results of proliferation-related genes in KG-1α cells and Kasumi cells treated with Siglitstat and ABT-199 for 24 hours. The results show that in cells treated with Siglitstat, the downstream signaling pathway of PI3K, Raf / MEK / ERK, is downregulated, and the phosphorylation level of ERK protein is reduced. It enters the cell nucleus and regulates the expression levels of multiple genes, such as the downregulation of the downstream proliferation-related gene c-Myc in this pathway.

[0096] Figure 7B The Western blot analysis results of apoptosis-related genes in KG-1α cells and Kasumi cells treated with Siglitstat and ABT-199 for 24 hours showed that the PI3K / AKT pathway was downregulated in cells treated with Siglitstat, the expression of pro-apoptotic protein Bax was upregulated, and the expression of anti-apoptotic proteins Bcl-2, Bcl-xL, and Mcl-1 was downregulated; the expression of anti-apoptotic protein Bcl-2 in cells treated with Bcl-2 inhibitor ABT-199 was significantly downregulated; Siglitstat combined with ABT-199 induced apoptosis in AML cell lines faster.

[0097] Example 6

[0098] Evaluation of the killing effect of the combined drug composition on AML cells at the animal level

[0099] The specific operation method is as follows:

[0100] (1) Construction of PDX mouse model

[0101] Collect 5×10 5 Primary AML cells were injected into NOD-Prkdc cells via tail vein. - / - IL - / - The tumors were formed in NSG mice, which were purchased from the Experimental Animal Center of Xiamen University and were raised by the Experimental Animal Center.

[0102] (2) The control group, ABT-199 group, sitagliptin group, and the combination group were set up separately.

[0103] About 14 days after injection, ABT-199 was administered at a dose of 50 mg / kg / day and Siglitana sodium was administered at a dose of 10 mg / kg / day, with the day of administration as day 0, and the administration was carried out by gavage for 14 days. There were 9 mice in each group, of which 4 mice had their leg bone marrow taken for flow cytometry analysis, and 5 mice had their survival rates calculated.

[0104] Fig. 8A This is the appearance of the spleen of each group of mice in the PDX mouse model 14 days after administration; Figure 8B This is a statistical chart of the spleen weight of each group of mice in the PDX mouse model 14 days after administration of the drug; the results show that the spleen of mice in the combination group of the two drugs is significantly smaller than that of the control group and the single drug group. Figure 8C This is a statistical result of the ratio of human CD45 positive cells in the bone marrow of the leg bones of the PDX mouse model 14 days after drug administration. The results show that the ratio of human CD45 positive cells in the bone marrow of the mice in the combination group of the two drugs is lower than that in the control group and the single drug group. Fig.8D This is a statistical chart of the survival rate of the PDX mouse model 14 days after administration. In summary, sitagliptin combined with ABT-199 can significantly inhibit the tumor formation process of the PDX model.

[0105] The present invention illustrates a combined pharmaceutical composition for preventing and / or treating acute myeloid leukemia and its application through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0106] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0107] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. Use of a combined pharmaceutical composition in the preparation of a drug for alleviating or treating acute myeloid leukemia, characterized in that: The combined pharmaceutical composition consists of a PPAR agonist and a Bcl-2 inhibitor; The PPAR agonist is sitagliptin sodium; The Bcl-2 inhibitor is ABT-199.

2. Use of the combined pharmaceutical composition according to claim 1 in the preparation of a drug for alleviating or treating acute myeloid leukemia, characterized in that: The combined pharmaceutical composition is a single compound preparation or a combination of two separate preparations.

3. Use of the combined pharmaceutical composition according to claim 1 in the preparation of a drug for alleviating or treating acute myeloid leukemia, characterized in that: The combined pharmaceutical composition is a combination of two separate preparations, and the two separate preparations are administered simultaneously or sequentially.

4. Use of the combined pharmaceutical composition according to claim 2 or 3 in the preparation of a drug for alleviating or treating acute myeloid leukemia, characterized in that: The preparation is in any pharmaceutically acceptable dosage form.